A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients

RATIONALE: The hypomethylating agent 5-azacytidine has been approved in Europe for patients with intermediate 2 and high (i.e., higher) risk myelodysplastic syndrome according to the International Prognostic Scoring System (IPSS). A total of 91% of all first responses in higher risk patients occur w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Medicine (Baltimore)
Main Authors: Spetsieris, Nikolaos, Diamantopoulos, Panagiotis, Zervakis, Konstantinos, Giannakopoulou, Nefeli, Rougala, Niki, Garefalakis, Georgios, Skarlatou, Vasiliki, Viniou, Nora-Athina
פורמט: Artigo
שפה:Inglês
יצא לאור: Wolters Kluwer Health 2018
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944567/
https://ncbi.nlm.nih.gov/pubmed/29703015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000010505
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים